# US 11,433,064 B2 · Methods of using c-Met modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,064 B2
- Document ID: US11433064B2
- Status: Granted
- Kind: B2
- Application number: 16/919,562
- Filed: 2020-07-02
- Published: 2020-10-22
- Granted: 2022-09-06
- Earliest claimed: 2009-08-07
- Assignees: Exelixis, Inc.
- Applicants: Exelixis, Inc.
- Inventors: Dana T. Aftab; Thomas Mueller; Aaron Weitzman; Jaymes Holland
- Web page: https://patentgrep.com/patent/US11433064B2

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61K 31/015: carbocyclic
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 2121/00: Preparations for use in therapy
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 215/22: attached in position 2 or 4
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.

## Claims

### Claim 1

A method of treating brain cancer, wherein the method comprises administering to a patient in need of the treatment 40 mg of:
or a pharmaceutically acceptable salt thereof, in combination with one or both of temozolomide (TMZ) and radiation, wherein the brain cancer is glioblastoma.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound is administered as the (L)-malate salt as depicted in the following structure:

### Claim 3 (depends on 2)

The method according to claim 2, wherein the compound or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 4 (depends on 1)

The method according to claim 1, comprising one or more additional treatments, wherein the one or more additional treatment(s) are selected from (1) surgery, (2) one or more additional chemotherapeutic agent(s), (3) one or more hormone therapy(s), (4) one or more antibody(s), (5) one or more immunotherapy(ies), and (6) radioactive iodine therapy.